Theromics has appointed Andrew C. Zeringue as Chief Executive Officer. With nearly 20 years of leadership experience in interventional oncology and thermal ablation, Zeringue will guide the company’s next phase of growth as it advances its HeatSYNC™ gel platform for minimally invasive cancer treatment toward FDA clearance and commercialization.
MassVentures’ START program awarded Theromics Inc. funding to advance innovative technologies, including their injectable nanogel for cancer ablation and drug delivery. Theromics, alongside other awardees, are pioneering solutions to critical challenges, supporting Massachusetts’ economic growth, and transforming health, energy, and environmental industries.
Theromics Inc. received a $1 million NSF grant to advance HeatSYNC™, a nano-polymer gel for improved ablation therapy and targeted drug delivery. CEO Ron Murphy highlights its potential in reducing side effects. Dr. Bruce Lee joins as a medical advisor, focusing on women’s health innovations and FDA clearance efforts.
Theromics Inc. secured the financing to advance its HeatSYNC™ gel, a novel thermal accelerant for optimizing soft tissue thermal ablations. The funds will support FDA testing, with research underway at prestigious institutions. John L. Brooks III joins the board, bringing significant expertise in life sciences.
Theromics Inc., a Massachusetts-based medical device innovator, has received a National Science Foundation STTR Phase I grant to advance its HeatSYNC™ thermal accelerant gel. Designed for interventional radiology, HeatSYNC™ enhances soft tissue ablation by expanding treatment areas more efficiently, promising improved outcomes and safety in minimally invasive tumor treatments.
West Bridgewater, MA, April 21, 2019 – Theromics Inc. has announced the appointment of Ron Murphy as its new CEO, effective April 18, 2019, succeeding Thomas Ryan. Murphy expressed his enthusiasm about working with Dr. Dupuy and Dr. Park to commercialize innovative technologies aimed at optimizing thermal ablation and reducing cancer recurrence rates. The company also welcomes Dr. Joseph Amaral to its Board of Directors, who emphasized the significance of their advancements in minimally invasive tumor management.
